NCT06940297View on ClinicalTrials.gov

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

August 15, 2031

Study Completion Date

August 15, 2031

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

BIOLOGICAL

Ciltacabtagene Autoleucel

Given IV

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Cyclophosphamide

Given IV

DRUG

Dasatinib

Given PO

DRUG

Fludarabine

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

DRUG

Quercetin

Given PO

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT06940297 - Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter